Mark Merriman

4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase.

M. Batchelor, Andrew Gill, I. Whitcombe, 2008, Bioorganic & medicinal chemistry letters.

Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ

R. Allen, J. Delgado, Lindsay K Shuttleworth, 2017, The Journal of Pharmacology and Experimental Therapeutics.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

J. Sludden, Y. Drew, D. Jamieson, 2016, European journal of cancer.

A Phase I pharmacokinetic and pharmacodynamic study of the oral MEK inhibitor , WX-554 , in patients with advanced solid tumours

Vicky, J. Sludden, Y. Drew, 2016 .

An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis

M. Herrmann, Helen T Horsley, D. Weitz, 2022, Frontiers in Pharmacology.

Fused thiophene derivatives as MEK inhibitors.

C. Meier, R. Allen, M. Hutchings, 2012, Bioorganic & medicinal chemistry letters.

CDP840

Z. Huang, M. Perry, D. Baldock, 2007, Cell Biochemistry and Biophysics.

Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors.

R. Owens, M. Merriman, R. Allen, 1999, Biochemical pharmacology.